Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zylera Pharmaceuticals has launched Relamine in the US, a prescription drug for osteoarthritis that helps to reduce joint swelling and control pain while slowing the onset and progression of the illness.
Subscribe to our email newsletter
“Relamine can help reduce the swelling in the joints, control joint pain associated with osteoarthritis, reduce the onset and progression of osteoarthritis and can be used in combination with other available treatments,” said Dr Philip Tabbiner, CEO of Zylera Pharmaceuticals.
Zylera said Relamine would be the first product to contain pharmaceutical quality glucosamine, chondroitin and primorine.
There have been several large clinical trials that show the benefits of chondroitin and glucosamine in treating the pain associated with osteoarthritis. One such study was designed to rigorously evaluate the efficacy and safety of these agents alone and in combination when taken over a 24-week period.
The study measured the effects of taking glucosamine alone, chondroitin alone, a glucosamine-chondroitin combination or celecoxib alone against placebo in 1,258 people with mild or moderate-to-severe pain from knee osteoarthritis. The results of this study found that patients with moderate-to-severe pain had significant improvement in osteoarthritis of the knee after 24 weeks of treatment with chondroitin and glucosamine.